The Polymer Drug Conjugates Market is expected to grow at a 32.0 % CAGR during the forecast period for 2023-2031.
Key Industry Insights & Findings from the Report:
- Growing demand for targeted drug delivery is driving the polymer-drug conjugates market.
- The increasing incidence of cancer, hepatitis, and other chronic conditions is fueling the need for more effective therapies, boosting the demand for polymer-drug conjugates.
- North America dominated the market and accounted for a global revenue share in 2023.
- The absence of established and improved preclinical or clinical approaches for evaluating polymer-drug conjugate stability, tumour penetration, metabolism, and toxicity is a challenge for the polymer-drug conjugate market.
Nano-sized pharmaceuticals known as polymer-drug conjugates are utilised to treat cancer and hepatitis. Polymers that are sensitive to certain enzymes prevalent in sick tissue are now being developed. Enzymatic activity and acidity in polymer-drug conjugates can degrade conventional polymers like cellulose and chitin. The Polymer Drug Conjugates Market is expected to expand rapidly during the forecast period, owing to strong growth in the pharmaceutical industry, particularly in the United States, and heavy investments in medical R&D, which has resulted in the development of technologically advanced medical devices and equipment. Since medical polymers are widely used in the production of pharmaceutical medications, substantial growth in the pharmaceutical sector in recent years has resulted in an increase in demand for medical polymers, which will boost industry share during the projected period.
The absence of established and improved preclinical or clinical approaches for evaluating polymer-drug conjugate stability, tumour penetration, metabolism, and toxicity is hindering polymer-drug conjugate market expansion. With the restricted use of polymer-drug conjugates, the market for polymer-drug conjugates is expected to grow slowly. The benefits of minimally invasive surgery, which include shorter hospital stays, faster recovery times, and minor bleeding and discomfort, increase their appeal. Because of the rising preference for these techniques over traditional surgery, the use of specific medical equipment has decreased, potentially hindering market growth.
Competitive Landscape
Some major key players in the Polymer Drug Conjugates Market:
- 3S Bio,
- Abeona Therapeutics,
- Abramson Cancer Center,
- Access Pharmaceuticals,
- Adama, Eyetech,
- Ferring,
- Flamel Technologies,
- Genentech,
- GlaxoSmithKline,
- Gowan,
- Gynecologic Oncology Group Foundation,
- JenKem Technology,
- Landec,
- Lipotek
Market Segmentation:
The Polymer Drug Conjugates Market is segmented on the basis of product type and application. Based on product type, the market is segmented as Polymer-Dox Conjugates, Polymer-Paclitaxel Conjugates, Polymer-Camptothecin Conjugates, and Polymer-Platinate Conjugates. Based on application, the market is segmented as Cancer Treatment, Leukemia, Hepatitis, and Others.
Based On Product Type, The Polymer-Paclitaxel Conjugates Segment Is Accounted As A Major Contributor In The Polymer Drug Conjugates Market.
Paclitaxel, derived from the bark of the Pacific Yew tree, is one of the most potent anticancer drugs available for the treatment of ovarian, breast, and lung cancer. Currently, commercial-scale paclitaxel bulk is manufactured from the Taxus chinensis cell line. Polymer paclitaxel conjugates gain ground in three areas robust conjugation chemistry, ease of large-scale manufacturing, and simple formulation. With their sluggish elimination from the kidney and improved penetration and retention effects, polymer-paclitaxel conjugates are projected to have a longer plasma half-life and a high tumor accumulation. Paclitaxel, on the other hand, has low bioavailability due to its low water solubility.
Based On Application, The Leukemia Segment Is Accounted As A Major Contributor To The Polymer Drug Conjugates Market.
Leukemia is a hematologic malignancy that primarily affects adults and the bone marrow, lymphatic system, and blood cells. The factors such as exposure to pesticides and paint, smoking history, and occupational exposure to chemicals are some major contributors to the growth of leukemia cases. Traditional cancer therapies, such as surgery, chemotherapy, and radiation, may result in inadequate cancer eradication or the destruction of normal cells. Nanotechnology addresses the shortcomings of these traditional approaches by serving as a guide in surgical tumor removal, directly targeting chemotherapies, and being selective to malignant cells. 5 This innovative device can lower the risk to the patient while also increasing the likelihood of survival, thus increasing the use of polymer drugs conjugate. Growing R&D activities and technological development are projected to provide a variety of new opportunities that will benefit the growth of the Polymer Drug Conjugates Market during the forecast period.
The North American Polymer Drug Conjugates Market Holds A Major Revenue Share In The Region.
North America is likely to hold a chief position in the global polymer-drug conjugates market because of the rising number of clinical trials in the United States. The region's ageing population and the prevalence of chronic diseases have increased the demand for medical devices. This is projected to drive demand for medical polymers in equipment manufacturing over the forecast period. Rising demand for medical polymers in pharmaceutical medications and the rapid expansion of pharmaceutical enterprises in Mexico and Canada are expected to drive growth even further. Increasing government investments in the healthcare sector and an expanding home healthcare market are expected to boost demand for medical equipment over the forecast period, and the Polymer Drug Conjugates Market would be positively influenced.
Recent Developments:
- In December 2022, Ferring Pharmaceuticals received FDA approval for Asitvaran (nadofaragene firadenovec-vncg), a novel gene therapy using adenovirus vectors, to treat high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) in adults with carcinoma in situ (CIS) with or without papillary tumours.
Polymer Drug Conjugates Market Report Scope
|
Report Attribute |
Specifications |
|
Growth rate CAGR |
CAGR of 32.0 % from 2023 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
Product Type, Application |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
3S Bio, Abeona Therapeutics, Abramson Cancer Center, Access Pharmaceuticals, Adama, Eyetech, Ferring, Flamel Technologies, Genentech, GlaxoSmithKline, Gowan, Gynecologic Oncology Group Foundation, JenKem Technology, Landec, and Lipotek. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
